Für einen optimalen Ausdruck erlauben Sie bitte den Druck von Hintergrundfarben und -bildern

(Nuvilex Inc) A0RGMH Eine neue Perle!


Seite 1 von 3
Neuester Beitrag: 13.09.17 17:13
Eröffnet am: 06.02.14 13:29 von: trader--38 Anzahl Beiträge: 68
Neuester Beitrag: 13.09.17 17:13 von: sweetmandy Leser gesamt: 9.821
Forum: Hot-Stocks   Leser heute: 4
Bewertet mit:
2


 
Seite: < 1 | 2 | 3 >  

297 Postings, 1690 Tage trader--38(Nuvilex Inc) A0RGMH Eine neue Perle!

 
  
    #1
2
06.02.14 13:29
42 Postings ausgeblendet.
Seite: < 1 | 2 | 3 >  

222 Postings, 1309 Tage Kampfschwein300Ist

 
  
    #44
17.07.16 17:24
Hier jemand noch dabei ?  

2323 Postings, 2551 Tage GoldenStockZwar schon etwas her....

 
  
    #45
10.10.16 13:11
aber ich denke PHARMACYTE wird im allgemeinen POT-Anstieg auch bald loslegen.
Vor 2-3 Jahren - beim Anstieg auch vorne mit dabei.
Bei 0,03  Euro - Cent durchaus eine Wette wert.
Kann durchaus in 1-2  Monaten auch wieder ( vielleicht ) bei 20-30 Cent stehen......
Werd versuchen - heute günstig noch ein paar Shares zu bekommen !!!
Mal sehen..  

2323 Postings, 2551 Tage GoldenStockSag nur GW Pharmaceuticals heute ca. 3 Mrd. Euro

 
  
    #46
10.10.16 13:16
wert.
Ist zwar ein langer Weg  - und die Unternehmen nicht ganz vergleichbar.
Aber wer weiß wo Pharmacyte in 1-2 Jahren steht ??
Vielleicht auch plötzlich bei 1-2 Euro/Dollar ???
 

222 Postings, 1309 Tage Kampfschwein300News

 
  
    #47
10.10.16 20:54
LAGUNA HILLS, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has advanced into a new and promising phase of research at the University of Northern Colorado (UNCO) in its quest to develop targeted cannabinoid-based chemotherapy utilizing the Cell-in-a-Box® technology.

“The work at UNCO is just one of the programs actively underway at PharmaCyte,” commented the Chief Executive Officer of PharmaCyte, Kenneth L. Waggoner. “With our preliminary work complete, we are now looking forward to the possibility of making significant progress in the development of targeted cannabinoid-based chemotherapy. The approach being used for our cannabinoid-based chemotherapy is the same as we are using for our pancreatic cancer therapy.”....

Link: http://finance.yahoo.com/news/...binoid-research-shows-132000820.html



Ich denke hier, werde ich auch nochmals eine kleine posi. nachkaufen. Bei mir stehen gerade -80% :(
 

222 Postings, 1309 Tage Kampfschwein300News

 
  
    #48
25.10.16 21:16
LAGUNA HILLS, Calif., Oct. 24, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that Manuel Hidalgo, MD, PhD has agreed to serve as the Principal Investigator (PI) for PharmaCyte’s clinical trial in patients with locally advanced, inoperable pancreatic cancer (LAPC). Dr......

Link: https://globenewswire.com/news-release/2016/10/24/...nical-Trial.html  

222 Postings, 1309 Tage Kampfschwein300News

 
  
    #49
16.11.16 21:55
PharmaCyte Biotech Now Awaits U.S. FDA to Advance Pancreatic Cancer Therapy into Pivotal Clinical Trial
Marketwired PharmaCyte Biotech, Inc.
6 hours ago


NEW YORK, NY--(Marketwired - November 16, 2016) - PharmaCyte Biotech (PMCB) has arrived at the door of U.S. FDA and awaits a pre-IND meeting with the agency. After years of surrounding its signature live-cell encapsulation technology, Cell-in-a-Box®, with some of the brightest minds in pancreatic cancer and fine-tuning its therapy and clinical trial design, the small biotech has reached the final test before it can begin its pivotal clinical trial in advanced pancreatic cancer.

Link: http://finance.yahoo.com/news/...-biotech-now-awaits-u-141500257.html  

222 Postings, 1309 Tage Kampfschwein300Heute

 
  
    #50
17.11.16 19:17
Plus 60% an der Otc. Mal gucken wie sich das weiter entwickelt. Bis jetzt noch nicht nachgekauft.  

222 Postings, 1309 Tage Kampfschwein300News

 
  
    #52
1
29.11.16 18:13
LAGUNA HILLS, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that a Pre-Investigational New Drug (Pre-IND) meeting with the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) has been granted by the FDA. During the meeting with representatives from CBER, they will respond to PharmaCyte’s previously submitted questions to the FDA as part of a Pre-IND information package related to PharmaCyte’s clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).

Link: http://finance.yahoo.com/news/...otech-granted-fda-pre-140000237.html  

2323 Postings, 2551 Tage GoldenStock50 Cent oder 1 Euro !?

 
  
    #53
1
08.12.16 22:26
Was meint hier geht dieses Jahr noch bei PMCB ?
Schwung ist kräftig drin die letzten Tage, gut das ich bei 0,03 nachgekauft habe...... :-)
Was meint ihr , wie gehts weiter ?  

222 Postings, 1309 Tage Kampfschwein300Glückwunsch

 
  
    #54
09.12.16 07:24
das du nachgekauft hast. Ich Volldepp hab nämlich nicht nachgekauft. Wollte immer im Geldkurs rein :(.
Nach 2 Jahren minus 80% bin ich jetzt 2€ im Plus ;). Ich warte noch auf einen kleinen Rücksetzer dann wird nachgekauft.  

974 Postings, 2079 Tage celi-michileg ich mir mal auf die watch-list

 
  
    #55
09.12.16 07:36
mal sehen, wie es die Tage weiter geht...
für einen Einstieg jetzt ist es mir zu riskant !  

222 Postings, 1309 Tage Kampfschwein300Bin

 
  
    #56
11.12.16 12:37
Gespannt wie es nächste Woche weiter geht.  Nachgekauft hab ich bis jetzt noch nicht.  

222 Postings, 1309 Tage Kampfschwein300Aktuelles

 
  
    #57
27.12.16 16:30
PharmaCyte Biotech’s Cannabinoid Therapy May Offer Potential for Childhood Brain

Weiterempfehlen
December 27, 2016 09:30 ET | Source: PharmaCyte Biotech, Inc.
LAGUNA HILLS, Calif., Dec. 27, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that recent research performed at the Ann and Robert H. Lurie Children's Hospital of Chicago and Northwestern University’s Feinberg School of Medicine and published in the journal Child’s Nervous System provides further support for PharmaCyte’s efforts to develop a targeted cannabinoid-based chemotherapy for brain cancer utilizing its

link: http://globenewswire.com/news-release/2016/12/27/...rain-Cancers.html

Habe letzte Woche mit einer kleinen posi. Nachgekauft
 

222 Postings, 1309 Tage Kampfschwein300Aktuell

 
  
    #58
04.01.17 16:18
AGUNA HILLS, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be meeting with the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) on Tuesday, January 17, 2017. The meeting is to discuss numerous aspects of PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer.........



Link:http://globenewswire.com/news-release/2017/01/04/...ate-with-FDA.html  

222 Postings, 1309 Tage Kampfschwein300News

 
  
    #59
19.01.17 09:03
PharmaCyte Biotech to Hold Shareholder Call



January 18, 2017 09:00 ET | Source: PharmaCyte Biotech, Inc.
LAGUNA HILLS, Calif., Jan. 18, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Chief Executive Officer Kenneth L. Waggoner will conduct a shareholder conference call at 4:30 p.m. EST on Tuesday, February 7, 2017.

Link: http://globenewswire.com/news-release/2017/01/18/...eholder-Call.html

 

222 Postings, 1309 Tage Kampfschwein300News

 
  
    #60
30.01.17 22:22
harmaCyte Biotech Retains Facet Life Sciences to Guide Pancreatic Cancer Therapy Development Lifecycle with FDA






January 30, 2017 09:00 ET | Source: PharmaCyte Biotech, Inc.
LAGUNA HILLS, Calif., Jan. 30, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, officially announced today that PharmaCyte has retained Facet Life Sciences, Inc. (Facet) to guide PharmaCyte through its pancreatic cancer therapy development lifecycle with the U.S. Food and Drug Administration (FDA). Facet has been working with PharmaCyte and Translational Drug Development (TD2) since September 2016 and was instrumental in expediting PharmaCyte’s pre-IND meeting with the FDA.....





Link:http://globenewswire.com/news-release/2017/01/30/...cle-with-FDA.html  

222 Postings, 1309 Tage Kampfschwein300Shareholder Call

 
  
    #61
07.02.17 19:38
Von Facebook:
Join PharmaCyte Biotech today on its Shareholder Call -
Date: February 7, 2017
Time: 4:30 p.m. EST
Tel. Number: (515) 739-1030...
Mehr anzeigen
Treten sie heute bei der Pharmacyte Biotech auf ihren Aktionär-Call -
Datum: 2017 Februar 2017
Zeit: 4:30 Uhr est
.. Zahl: (515) 739-1030
Zugang: 915-603-449  

222 Postings, 1309 Tage Kampfschwein300Frage

 
  
    #62
08.02.17 11:07
an euch. Hat da jemand von euch  einer angerufen?  

222 Postings, 1309 Tage Kampfschwein300Update

 
  
    #63
08.02.17 20:34
Link:http://globenewswire.com/news-release/2017/02/08/...-Information.html


February 08, 2017 09:00 ET | Source: PharmaCyte Biotech, Inc.
LAGUNA HILLS, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that an audio recording of the company’s shareholder call, which was held on February 7, 2017, by the Chief Executive Officer of PharmaCyte, Kenneth L. Waggoner, is now available for playback. PharmaCyte also announced that the remaining unanswered questions and answers have been recorded and are available playback as well.....


Gehen bei euch die Links? Bei mir läuft nichts.  

222 Postings, 1309 Tage Kampfschwein300News:

 
  
    #64
13.02.17 16:24
LAGUNA HILLS, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today discussed the comparator arm for its upcoming clinical trial and provided additional clarification on its recent pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding its upcoming clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).

In the company’s upcoming trial, the comparator arm that PharmaCyte’s pancreatic cancer therapy will be compared to is the combination of the cancer drug 5-fluorouracil (FU) and the compound leucovorin (LV). The necessary and quick decision was made by Dr. Manuel Hidalgo, the Principal Investigator for the upcoming clinical, Dr. Daniel Von Hoff with Translational Drug Development (TD2), the CRO for PharmaCyte’s clinical trial, and Dr. Matthias Löhr, the Chairman of PharmaCyte’s Medical and Scientific Advisory Board.......




Link: http://globenewswire.com/news-release/2017/02/13/...-Opportunity.html  

206 Postings, 330 Tage sweetmandy* News *

 
  
    #65
18.04.17 16:08
http://web.tmxmoney.com/...sid=8745582906597516&qm_symbol=PMCB:US  

2221 Postings, 2913 Tage tolksvarnicht mehr lange auf entscheidung

 
  
    #66
17.05.17 12:43
PharmaCyte Biotech Updates IND Submission Process in Interview with Facet Life Sciences



LAGUNA HILLS, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today released an educational, interview-style Q&A article with Sarah DeMare, the Product Development Champion with Facet Life Sciences and U.S. Agent for PharmaCyte, who discusses the IND submission process for PharmaCyte’s upcoming clinical trial in locally advanced pancreatic cancer (LAPC).


Since coming to an understanding with the FDA on a path forward after PharmaCyte’s pre-IND meeting in January, is there a list of items that you can share with us that when completed will allow PharmaCyte to file its Investigational New Drug application (IND)?

Sarah DeMare: “The single most important item PharmaCyte needed to learn from the FDA at the pre-IND meeting was the acceptability of PharmaCyte’s proposed cell line. Without that understanding, PharmaCyte was unable to move forward with the manufacture of its product candidate for the LAPC clinical trial.”

“An IND encompasses many things, dealing with the manufacture and characterization of the product candidate, the clinical study design and nonclinical studies. PharmaCyte’s therapy for pancreas cancer has undergone or been part of several studies, so incorporation of that information into the IND is not ‘rate limiting’ or ‘slowing down the progress towards submitting an IND.’ The clinical study design that PharmaCyte agreed to undertake after meeting with the FDA is currently being drafted. This is also not rate limiting. To conduct the clinical trial, PharmaCyte will need to manufacture, test and release a Master Cell Bank, a Working Cell Bank and the encapsulated live cells. This information is also required to be described and documented in detail in the IND.  The manufacture of these items is the rate limiting factor involved in submitting the IND.”

“Before the IND is filed, the following items must be available for inclusion:

(a)  Documentation of preclinical work done on the cells.
(b)  Toxicology studies.
(c)  Documentation of preclinical work done on the capsules themselves.
(d)  A wide array of CMC (Chemistry, Manufacturing and Controls) documentation that verifies that the final biologic product (the encapsulated cells) has been produced under current Good Manufacturing Practices (cGMP)-compliant conditions.
(e)  Labeling for the final investigational biologic product.
(f)  Previous evidence of human experience with the pancreas cancer therapy (low-dose ifosfamide plus Cell-in-a-Box® encapsulated genetically modified human cells).
(h) The Investigator’s Brochure.
(i)  The Informed Consent Form
(j)  The Case Report Form”

Can you talk about the items on the list in relation to PharmaCyte’s progress and what further rate limiting steps are on the path to filing the IND?

Sarah DeMare: “Documentation of work done on items (a), (b) and (c) and a significant amount of material concerning item (d) have been accumulated to date. As for item (f), publications of Phase 1/2 and Phase 2 trials that were published in scientific journals are “in-house,” as are original clinical reports of those clinical trials. The clinical trial protocol is nearing the “final” stage. Items (h), (i) and (j) will be written by Translational Drug Development (TD2), the Contract Research Organization (CRO) PharmaCyte has retained to conduct the clinical trial in the U.S. and oversee its conduct in Europe by Clinical Network Services (CNS).”

“The rate limiting step to being able to file the IND and, ultimately, begin the clinical trial is the manufacture of the combination drug product. For live cell-based products, a Master Cell Bank or ‘MCB’ first needs to be manufactured, characterized, tested and released. The speed at which the MCB can be produced is dependent on several different things. First, is the availability of starting materials. Some starting materials can have a significant lead-time when ordering, and you cannot begin manufacture until you have all your starting materials. Second, is the growth rate of the live cells. Cells grow at different rates. There isn’t much that can be done to speed up that process.  Unfortunately, it is not a 1 to 2-day event. “

“Also, when working with a Contract Manufacturer Organization (CMO) to make your cell bank, some things are out of your control. For example, scheduling. CMOs typically schedule their manufacturing rooms out months in advance for their clients, so sometimes you need to wait in the queue for your turn. In addition, and perhaps most importantly, the MCB needs to be tested to ensure its quality, which is of utmost importance. These tests are also not tests that can always be done quickly. Sterility is a good example. This test is mandatory to ensure the sterility of your MCB and takes approximately 6 weeks to obtain results.”

“The purpose of creating a MCB is to provide a repository of live cells that are essentially identical to the material tested in clinical trials and throughout the development process. After creating a MCB, a Working Cell Bank or ‘WCB’ must be manufactured. Creation of a WCB is an important step, as it allows your Master Cell Bank to have a longer useful life.”

“This is an important point, and it’s worth illustrating. Let’s say you can make 300 vials in your MCB. Let’s also say that each vial of cells can produce enough drug product to treat 100 patients. That would mean you could potentially treat 30,000 patients with the entire MCB. Sounds like a lot, right?  Maybe, but this MCB will need to provide cells to patients for years to come. At some point in the future, the MCB will be depleted. This would require another MCB to be produced, and in such a complex system there would be no guarantee that the original cells could be duplicated exactly. In the best case, this means extensive testing would be needed to prove that the new MCB is equivalent to the old MCB.”

“If those tests reveal differences that could affect efficacy, a new clinical study may be needed to demonstrate that the new MCB is equivalent to the old MCB. There is always the potential that it will not be equivalent. That is the situation the FDA would like to avoid, which is why a Working Cell Bank is needed.  To make a WCB, you take one vial of your Master Cell Bank and grow it into more vials to become your Working Cell Bank. So, theoretically, you could get 200 vials of your Working Cell Bank from 1 vial of your Master Cell Bank. Assuming one vial of your WCB still treats 100 patients, you could treat 20,000 patients from only 1 vial of Master Cell Bank. Using this example, a 200-vial Master Cell Bank could treat up to 4 million patients. Compare that to the 30,000 patients you could treat with the entire Master Cell Bank, and you can see that having a WCB allows your MCB to go much further and last much longer.”

“Producing a Working Cell Bank is similar to the Master Cell Bank in that it takes time for the live cells to grow, and you need to test and release the live cells.  Sterility testing is still required, and it still takes 6 weeks to perform.”

“Finally, with the Working Cell Bank ready, the drug product can be manufactured, tested and released. The FDA will want to see the test results that demonstrate the quality of the drug product in the IND. So, the IND cannot be filed until the testing of the drug product is completed.”

In your experience with the FDA, discuss the importance of following the FDA's guidance to the letter?

Sarah DeMare: “The FDA is most concerned with patient safety. So, while there may be opportunity to state that certain pieces of information will be available at a later date, those issues that directly impact patient safety are important to include in your IND. From a manufacturing perspective, for a product that is being injected into the body, sterility is of utmost importance to the FDA. Not only sterility of the live cells in the vials, but understanding the manufacturing process, the environment in which the cells were manufactured and where the starting materials came from are critically important. There is a lot of information about this to be described in detail in the IND.”

“Following the guidance that the FDA has provided at the pre-IND meeting gives the company the best chance of success at having the IND accepted after the 30-day period.”

What are the potential downsides to submitting an IND that doesn't follow the FDA's guidance to the letter?

Sarah DeMare: “The obvious answer is that if the FDA feels like there are concerns with patient safety, the FDA will place PharmaCyte on clinical hold until those concerns can be resolved. Depending on what the issues are, they may be resolved with some additional testing or characterization, perhaps describing something with a bit more clarity or providing site processes and procedures. The worst-case scenario would be if the FDA found an issue with the Master Cell Bank that could not be resolved and resulted in needing to manufacture the Master Cell Bank, Working Cell Bank and drug product again to the FDA’s satisfaction. This is why it is so important to make sure it is done right the first time.”

“Another less obvious answer is the impression it would leave on the FDA. A sponsor of an IND, like PharmaCyte, is going to have many opportunities to interact with the FDA on its path to a Biologics License Application (BLA) approval. An initial IND is that ‘first impression’ so to speak. Having a well thought out, well put together and well written IND with all of the required information can demonstrate to the FDA that the sponsor understands what needs to be done and is serious about the intent to bring an important and novel therapy to patients.”

If PharmaCyte, or any company for that matter, follows the FDA's guidance step by step on the path to filing an IND and the final submission is closely married to that which was discussed in the pre-IND meeting, is it your experience that the company can get through the 30-day period without comment from the FDA?

Sarah DeMare: “In my personal experience, there are always comments from the FDA during the 30-day wait. However, under the scenario you have described, the comments should be minor and the sponsor should be able to quickly respond to them without issue. For example, the FDA may ask for slight changes in wording to the protocol. However, those issues will be communicated and will need to be responded to within 30 days. The issues that arise during the 30-day window are almost always related to patient safety. It is very common for the FDA to send the ‘safe to proceed’ letter to the sponsor with a list of items for the sponsor to consider or complete over the course of development, but that doesn’t impede the sponsor from beginning its clinical trial.”

PharmaCyte will follow up this interview-style Q&A article with an additional interview with TD2 that will be more focused on the clinical trial, clinical sites, training, etc. and will discuss what work is being done in parallel with the work that is ongoing to complete the IND discussed by Ms. DeMare. It is this clinical-focused work that will allow PharmaCyte to begin its clinical trial almost immediately upon receiving the “safe to proceed” letter from the FDA—30 days after filing the company’s IND.
 

206 Postings, 330 Tage sweetmandy* news *

 
  
    #67
07.09.17 18:42
PharmaCyte strukturiert Vereinbarungen mit Austrianova zur Stärkung der Partnerschaft
LAGUNA HILLS, Kalifornien.
PharmaCyte Biotech, Inc. (OTCQB: PMCB), ein klinisches Bühnen-Biotechnologie-Unternehmen, das sich auf die Entwicklung zielgerichteter Zelltherapien für Krebs und Diabetes konzentriert, mit seiner Signatur-Live-Zell-Kapselungstechnologie, Cell-in-a-Box®, gab heute bekannt, dass es erreicht hat eine Vereinbarung mit Austrianova zur Umwandlung bestimmter Vereinbarungen zwischen ihnen nach einem verbindlichen Term Sheet (Term Sheet).

Das Term Sheet sieht vor, dass die Verpflichtung von PharmaCyte, Meilensteinzahlungen im Rahmen des Asset Purchase Agreement, des Diabetes Licensing Agreement und des Cannabis Licensing Agreement zu tätigen, in vollem Umfang beseitigt wird. Auch die Lizenzgebühren und die Unterlizenzgebühren werden in den beiden Lizenzvereinbarungen reduziert. Das Term Sheet ergänzt den Diabetes-Lizenzvertrag weiter, indem er den Umfang der lizenzierten Rechte erweitert, um die Kapselung aller Zelltypen und Zelllinien jeglicher Art, die jetzt existieren oder später identifiziert wurden, einschließlich Stammzellen in allen Stufen der Differenzierung und von jeder Quelle spezifisch zu decken entworfen, um Insulin für die Behandlung von Diabetes zu produzieren.

Das Term Sheet bietet auch PharmaCyte mit einem 5-jährigen Verweigerungsrecht an, falls Austrianova den Cell-in-a-Box®-Handelsnamen und die damit verbundene Technologie, das geistige Eigentum, die Geschäftsgeheimnisse und das "Know- wie "(assoziierte Technologien). Hierzu gehört auch das Recht, eine mit dem Cell-in-a-Box®-Verfahren verwendete Fertigungsstätte zu erwerben, sowie eine nicht exklusive Lizenz für das in diesem Verfahren verwendete spezielle Cellulosesulfat. Darüber hinaus hat Austrianova für einen Zeitraum von einem Jahr ab dem Datum des Term Sheet vereinbart, keine Anfragen über die potenzielle Akquisition von Cell-in-a-Box® und seinen Associated Technologies zu erbitten, zu verhandeln oder zu unterhalten.

PharmaCyte hat vereinbart, mit Austrianova 50% der finanziellen und nichtfinanziellen Gegenleistung zu teilen, die sie von Unterlizenzen im Rahmen des Asset Purchase Agreement, des Diabetes Licensing Agreement und des Cannabis Licensing Agreement erhält. PharmaCyte hat auch vereinbart, Austrianova $ 150.000 pro Monat für die nächsten 6 Monate zu zahlen. Prof. Walter H. Günzburg, Vorstandsvorsitzender der Austrianova, der derzeit als Chief Scientific Officer von PharmaCyte tätig ist, hat sich bereit erklärt, seine Arbeit für PharmaCyte ohne Barausgleich für den gleichen Zeitraum fortzusetzen.

Kenneth L. Wagoner, Chief Executive Officer von PharmaCyte, kommentierte die Umstrukturierung: "Wir haben fleißig mit Austrianova gearbeitet, um Wege zu finden, um unsere Interessen als Partner besser auf die Ziele von PharmaCyte auszurichten. Die Bestimmungen des Term Sheet machen genau das. Nicht nur hat Austrianova erhebliche finanzielle Zugeständnisse gemacht, so hat Austrianova vereinbart, uns ein Fahrzeug zur Verfügung zu stellen, mit dem wir Cell-in-a-Box® und seine Associated Technologies erwerben können, einschließlich der Fertigungsstätte, die die für unseren Pankreas benötigten lebenden Zellen einkapselt Krebstherapie und die anderen Therapien, die wir entwickeln, die die Cell-in-a-Box®-Technologie nutzen.

"Wir fühlten uns, dass die Sicherung des Rechts der ersten Ablehnung jetzt zwingend erforderlich war, da wir mit unserer geplanten klinischen Studie bei lokal fortgeschrittenem Bauchspeicheldrüsenkrebs vorankommen. Wir glauben auch, dass diese Änderungen dazu beitragen werden, die Partnerschaft zu stärken, die zwischen PharmaCyte und Austrianova bestand, da wir zunächst das Recht erworben haben, diese bemerkenswerte Technologie zu nutzen. "

Prof. Gunzburg, der Vorsitzende von Austrianova, sagte: "Die nächsten 6 Monate werden eine spannende Zeit in der weiteren Ausrichtung unserer jeweiligen Unternehmen sein. PharmaCyte war schon immer ein wichtiger Partner für die Austrianova, und wir freuen uns darauf, unsere gegenseitig vorteilhafte Beziehung zu intensivieren. "

Das Term Sheet erinnert an die Vereinbarung zwischen den Parteien, ihre Hauptverträge zu ändern. Diese Änderungen sind in den Prozess der Entwürfe und sollten abgeschlossen und von den Parteien in der nahen Zeit unterzeichnet werden.

https://web.tmxmoney.com/...id=8689806937094238&qm_symbol=PMCB:US  

206 Postings, 330 Tage sweetmandynews * update

 
  
    #68
13.09.17 17:13
PharmaCyte Biotech, Inc. (OTCQB: PMCB), ein klinisches Bühnen-Biotechnologie-Unternehmen, das sich auf die Entwicklung zielgerichteter Zelltherapien für Krebs und Diabetes konzentriert, mit seiner Signatur-Live-Zell-Kapselungstechnologie, Cell-in-a-Box®, gab heute die Ernennung von Alan bekannt Morell, Vorsitzender und Chief Executive Officer von Creative Management Partners, als strategischer Berater des Chief Executive Officer und Board of Directors.

Kenneth L. Wagoner, Chief Executive Officer von PharmaCyte, kommentierte den Termin und sagte: "Seit über einem Jahr haben wir noch keine Investor Relations oder Public Relations-Unternehmen gehabt, um das Interesse von PharmaCyte an der Investitionsgemeinschaft voranzubringen, wie man es normalerweise hätte eine Firma wie unsere. Wir fühlten uns, dass es nicht gut war, unsere Zeit und Geld zu nutzen, bis wir in unserer klinischen Entwicklung weiter waren.

"Wir haben jetzt den Punkt in unserem Lebenszyklus als Biotech-Unternehmen erreicht, wo wir eine komplette Geschichte haben, die wir endlich erzählen können. Durch Dr. Leonard Makowka, unseren Senior Strategic Advisor, wurden wir bei Alan Morell von Creative Management Partners eingeführt. Mit Mr. Morell ist unser Team eine einmalige Gelegenheit für uns. Es ist nicht eine, die ohne eine langjährige und sehr persönliche Beziehung zwischen Dr. Makowka und Herrn Morell gekommen wäre. In der Tat, alles, was Herr Morell tut und hat in seiner stellaren Karriere erreicht ist beziehungsweise angetrieben. Es ist durch seine Beziehungen, dass wir glauben, dass er wirksam sein wird, unsere Geschichte zu erzählen und es den richtigen Leuten zu erzählen. "

Herr Morell sagte: "Ich bin sehr geehrt, dem Team von PharmaCyte beizutreten. Es hat eine ernsthafte und beeindruckende Geschichte zu teilen - eine Geschichte, die noch zu erzählen ist. PharmaCyte ist bereit, die Art und Weise zu ändern, wie feste Krebsgeschwülste behandelt werden. Dies gilt besonders für eine der tödlichsten Formen von Krebs - Bauchspeicheldrüsenkrebs - ein Krebs, der meine Freunde und Familie berührt hat. Darüber hinaus sind die potenziellen Wachstumsmöglichkeiten bei zellulären Therapien mit der Cell-in-a-Box®-Technologie nahezu grenzenlos. "

Die Kompetenz von Herrn Morell liegt in der Unternehmensführung, dem Branding, der Medienstrategie, dem literarischen, Talentmanagement und der Produktlizenzierung. Creative Management Partners hat seinen Hauptsitz in Beverly Hills, Kalifornien, mit Niederlassungen in New York, Toronto und London. Mit über 30 Jahren in der Branche hat Herr Morell mehr als 2.500 Kampagnen mit Disziplinen in Beratungs-, Beratungs-, Literatur-, Fernseh- und Filmveranstaltungen sowie Live-Events in den Bereichen Unterhaltung, Sport, Kunst und Corporate America geführt.

Herr Morell hat auch Erfahrung in der Entwicklung von Wachstumsstrategie und Marktpositionierung für Kunden in der Healthcare-Branche. Dazu gehören die Identifizierung von Verbänden für Medienkampagnen mit Video-Pressemitteilungen, Social Media, Print Publikationen und Online-Publikationen. Er arbeitet auch regelmäßig mit Hunderten von Nachrichten-Mitgliedsorganisationen, darunter große Netzwerke wie FOX, MSNBC und CNBC, für Live-Auftritte und aufgenommene Interviews.

Herr Morell ist bereit, PharmaCyte vor einer Vielzahl von Medien zu platzieren. Diese Verkaufsstellen sind die echten Geschichtenerzähler. Auch die professionellen Beziehungen von Herrn Morell können zu einzigartigen Möglichkeiten für PharmaCyte führen, Kapital aus Quellen zu heben, die ein großes Interesse daran haben, dass das Ergebnis für Bauchspeicheldrüsenkrebs mit der Therapie von PharmaCyte dramatisch verbessert wird. Darüber hinaus, weil Herr Morell stellt zahlreiche Berühmtheiten in Hollywood und New York, kann er potenziell erweitern das Publikum, dass PharmaCyte weit über das hinaus, was eine traditionelle Investor Relations oder Public Relations-Unternehmen bieten könnte.

Herr Morell begann seine Karriere bei der International Management Group (IMG), wo er in zahlreichen Führungskapazitäten, darunter Corporate Vice President, tätig war. Er hat einen Abschluss von der University of Florida. Sein Buch, Social Media: Rebranding Outside the Clutter, wird im Herbst 2017 von iBooks veröffentlicht werden.

https://web.tmxmoney.com/...id=8015047001936336&qm_symbol=PMCB:US  

Seite: < 1 | 2 | 3 >  
   Antwort einfügen - nach oben